BE Semiconductor Industries: Important TCB Next order. Belgian telcos: Telenet weak Q1 commercially across the board, financials reasonable. D'Ieteren: Belgian April car registrations down 5%, VW down 11%. GBL: NAV per share above estimates. Kinepolis: US Peer Cinemark 1Q25 results a slight miss. KPN: VodafoneZiggo 1Q25 very weak, cut guidance on EBITDA, revenue after 2 months
Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results Press Release – No. 7 / 2025 Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results Copenhagen, Denmark, May 1, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 8, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the ...
After a disappointing set of FY24 results, the 1Q25 trading update is likely to be less eventful. Do expect though a larger Share Buyback (€250m INGF). The headwinds in both the US and Asset Management and the creeping restructuring costs in the US indicate that progress will slow. The ASR stake uncertainty and AEGON's inaction when shares reached highs in March suggest to us that a clearer response is needed here. AEGON should perhaps continue to shed businesses, as holding on to THB in Asia ev...
A director at VGP N.V. bought 15,800 shares at 77.496EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
We cut our EPS by 13% on lower attendance and our target price by 14% to €43, while factoring in slightly lower long-term growth and a slower M&A restart. The share price has underperformed by 20% YTD, reflecting a weak 1Q25, some specific country issues (Netherlands, Spain, France), macro fears and, we think, more longer term concerns that the industry cannot pull off a material recovery despite an improvement in content. We keep our BUY rating on: (1) Kinepolis self-help and, above all, its M&...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.